NR1I2 and tuberculosis: The current study examined the impact of genetic variations in CAR (NR1I3) and PXR (NR1I2) on plasma EFV exposure and CYP2B6 enzyme activity among TB-HIV co-infected patients on RIF-based first-line anti-TB drugs and EFV-based ART in Ethiopia.